Anti-angiogenic drugs, such as bevacizumab, an anti-VEGF monoclonal antibody, specifically target VEGF or its receptor to block the formation of new blood vessels, thus restricting the access of oxygen and nutrients to the tumor, thus making bevacizumab an excellent candidate for developing new targeted therapies [47,155,156,157,158]. This evidence concerns the gene VEGFA and neoplasm.